Revenue: As of FY2024 Q3, the actual value is USD 590.12 K.EPS: As of FY2024 Q3, the actual value is USD -0.01.EBIT: As of FY2024 Q3, the actual value is USD -1.973 M.<h3>Health Services Division</h3><ul><li>Revenue: Patient service revenue was $2,249,579 for the nine months ended September 30, 2024, a decrease of 51% from $4,602,081 in the same period in 2023.</li><li>Operating Expenses: Practice salaries and benefits were $1,546,806, a decrease of 41% from $2,635,065 in the same period in 2023. Other practice operating expenses were $1,221,272, a decrease of 32% from $1,799,530 in the same period in 2023.</li><li>Impairment Loss: An impairment charge of $716,000 was recorded for the NCFM Medical Database in the nine months ended September 30, 2024.</li></ul><h3>Digital Healthcare Division</h3><ul><li>Revenue: Subscription revenue was $48,161 for the nine months ended September 30, 2024, a decrease of 11% from $54,050 in the same period in 2023.</li><li>Operating Expenses: Selling, general, and administrative expenses were $2,444,386, a slight decrease from $2,621,951 in the same period in 2023.</li></ul><h3>Medical Distribution Division</h3><ul><li>Revenue: Product revenue was $91,694 for the nine months ended September 30, 2024, a decrease of 32% from $135,034 in the same period in 2023.</li><li>Operating Expenses: Cost of product revenue was $86,976, a decrease of 19% from $107,277 in the same period in 2023.</li></ul><h3>Cash Flow</h3><ul><li>Operating Cash Flow: Net cash used in operating activities was $2,750,520 for the nine months ended September 30, 2024, compared to $2,952,574 in the same period in 2023.</li><li>Financing Activities: Net cash provided by financing activities was $2,520,854, primarily from the issuance of notes payable and sale of common stock.</li></ul><h3>Future Outlook and Strategy</h3><ul><li>Core Business Focus: The company plans to profitably operate its Health Services business and continue investing in its Digital Healthcare business, including the HealthLynked Network.</li><li>Non-Core Business: The company completed the sale of its ACO/MSO Division on January 17, 2023, and may receive future proceeds from the sale if certain conditions are met.</li></ul>

HEALTHLYNKED CORP | 10-Q: FY2024 Q3 Revenue: USD 590.12 K